Teva Pharmaceutical Industries Limited (TLV:TEVA)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 71.58B |
| Revenue (ttm) | 56.02B |
| Net Income (ttm) | -528.98M |
| Shares Out | n/a |
| EPS (ttm) | -0.47 |
| PE Ratio | n/a |
| Forward PE | 7.25 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,439,926 |
| Average Volume | 1,387,664 |
| Open | 6,247.00 |
| Previous Close | 6,271.00 |
| Day's Range | 6,115.00 - 6,290.00 |
| 52-Week Range | 4,865.00 - 8,431.00 |
| Beta | 0.73 |
| RSI | 52.62 |
| Earnings Date | Nov 5, 2025 |
About TLV:TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.
Financial numbers in USD Financial StatementsNews
Medincell Partner Teva to Host Investor Call on Completed Phase 3 Olanzapine LAI Data Following Psych Congress 2025 Presentation
MONTPELLIER, France--(BUSINESS WIRE)--Regulatory News: Medincell (Paris:MEDCL): Data from the completed phase 3 SOLARIS trial to be presented at the 2025 Psych Congress Annual Meeting, taking place fr...
Teva to Host Conference Call to Discuss Data from the Completed Phase 3 SOLARIS Trial For Olanzapine LAI (TEV-‘749) on September 22, 2025 After Presentations at the Psych Congress Annual meeting
TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 202...
Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)
Insider Buying: David Mcavoy Acquires Shares in Teva Pharmaceutical Industries Ltd (TEVA)
TEVA Secures FDA Fast Track for Emrusolmin in MSA Treatment
TEVA Secures FDA Fast Track for Emrusolmin in MSA Treatment
Teva gets FDA fast track status for multiple system atrophy drug
Teva Pharmaceuticals (TEVA) Gains FDA Fast Track for MSA Treatment
Teva Pharmaceuticals (TEVA) Gains FDA Fast Track for MSA Treatment
Teva Pharmaceutical Industries Ltd (TEVA) Receives FDA Fast Track Designation for Emrusolmin in ...
Teva Pharmaceutical Industries Ltd (TEVA) Receives FDA Fast Track Designation for Emrusolmin in Treating Multiple System Atrophy | TEVA stock news
Colorado must face Teva's lawsuit over free allergy pen law
Colorado must face Teva Pharmaceutical Industries' lawsuit challenging a state law requiring it to provide free generic EpiPens to pharmacies, a federal appeals court said Friday.
Teva Pharmaceutical Industries Ltd (TEVA) Announces CEO Presentations at Upcoming Investor ...
Teva Pharmaceutical Industries Ltd (TEVA) Announces CEO Presentations at Upcoming Investor Conferences | TEVA stock news
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global ...
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September | TEVA Stock News
Teva to Present at Morgan Stanley Global Healthcare Conference and Bank of America Global Healthcare Conference in September
TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcom...
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major pl...
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
The FDA signed off on the first-ever weight-loss generic on Thursday, a knockoff of Novo Nordisk's Saxenda from Teva Pharmaceutical.
Teva gets FDA nod for generic version of Novo's weight loss drug
US FDA approves Teva Pharmaceuticals' generic obesity drug
The U.S. Food and Drug Administration has approved Teva Pharmaceuticals' cheaper generic version of Novo Nordisk's older weight-loss drug, Saxenda, the Israel-based company said on Thursday.
Teva's Pivot To (Innovative) Growth: Re-Rating Should Continue
Teva Pharmaceutical: Tariff Relief Clears The Way For Reinvention
Teva Debuts Autumn Winter 2025 Collection Inspired By “For Playground Earth”
GOLETA, Calif.--(BUSINESS WIRE)--Teva unveils AW25 footwear collection.
How Is The Market Feeling About Teva Pharmaceutical Indus?
Teva Pharmaceutical Indus's (NYSE: TEVA) short percent of float has fallen 6.62% since its last report. The company recently reported that it has 49.89 million shares sold short , which is 4.37% of a...
Teva Pharmaceutical continues gains for seven straight sessions
Teva wins FDA label expansion for migraine therapy Ajovy in children and adolescents
Teva (TEVA) stock in focus as the FDA expands label for its migraine therapy Ajovy for children and adolescents aged 6–17 years. Read more here.
US FDA approves Teva's Ajovy for migraine prevention in children
The U.S. Food and Drug Administration on Tuesday approved Ajovy, an injection made by Israeli drugmaker Teva Pharma , to help prevent migraines in children aged six and older who weigh 45 kilograms or...
Teva's Big Pharma Comeback: Why I Think The Market Is Still Missing The Upside
Teva CEO: Our supply chain puts us in a strong position
Richard Francis, Teva Pharmaceuticals CEO, joins CNBC's 'Money Movers' to discuss the company's most recent earnings report.